JPWO2022034044A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2022034044A5
JPWO2022034044A5 JP2023509418A JP2023509418A JPWO2022034044A5 JP WO2022034044 A5 JPWO2022034044 A5 JP WO2022034044A5 JP 2023509418 A JP2023509418 A JP 2023509418A JP 2023509418 A JP2023509418 A JP 2023509418A JP WO2022034044 A5 JPWO2022034044 A5 JP WO2022034044A5
Authority
JP
Japan
Prior art keywords
antibody
seq
amino acid
acid sequence
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023509418A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023537078A (ja
JP2023537078A5 (https=
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2021/072203 external-priority patent/WO2022034044A1/en
Publication of JP2023537078A publication Critical patent/JP2023537078A/ja
Publication of JPWO2022034044A5 publication Critical patent/JPWO2022034044A5/ja
Publication of JP2023537078A5 publication Critical patent/JP2023537078A5/ja
Pending legal-status Critical Current

Links

JP2023509418A 2020-08-10 2021-08-09 COVID-19を治療及び防止するためのSARS-CoV-2抗体 Pending JP2023537078A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063063862P 2020-08-10 2020-08-10
US63/063,862 2020-08-10
US202063112104P 2020-11-10 2020-11-10
US63/112,104 2020-11-10
PCT/EP2021/072203 WO2022034044A1 (en) 2020-08-10 2021-08-09 Sars-cov-2 antibodies for treatment and prevention of covid-19

Publications (3)

Publication Number Publication Date
JP2023537078A JP2023537078A (ja) 2023-08-30
JPWO2022034044A5 true JPWO2022034044A5 (https=) 2024-07-25
JP2023537078A5 JP2023537078A5 (https=) 2024-07-25

Family

ID=77595513

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023509418A Pending JP2023537078A (ja) 2020-08-10 2021-08-09 COVID-19を治療及び防止するためのSARS-CoV-2抗体

Country Status (11)

Country Link
US (2) US20220041694A1 (https=)
EP (1) EP4192860A1 (https=)
JP (1) JP2023537078A (https=)
KR (1) KR20230045613A (https=)
CN (1) CN116234577A (https=)
AU (1) AU2021325339A1 (https=)
BR (1) BR112023002234A2 (https=)
CA (1) CA3190280A1 (https=)
IL (1) IL300257A (https=)
TW (1) TW202221025A (https=)
WO (1) WO2022034044A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI4045533T3 (fi) 2020-03-26 2024-02-02 Univ Vanderbilt Ihmisen monoklonaalisia vasta-aineita vakavalle akuutille koronavirus 2 -hengityselinoireyhtymälle (sars-cov-2)
TW202342510A (zh) 2022-02-18 2023-11-01 英商Rq生物科技有限公司 抗體
JP2025514858A (ja) 2022-04-29 2025-05-09 アストラゼネカ・ユーケイ・リミテッド SARS-CoV-2抗体、及びその使用方法

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
IE922437A1 (en) 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
GB9206422D0 (en) 1992-03-24 1992-05-06 Bolt Sarah L Antibody preparation
WO1993022332A2 (en) 1992-04-24 1993-11-11 Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
JP4046354B2 (ja) 1996-03-18 2008-02-13 ボード オブ リージェンツ,ザ ユニバーシティ オブ テキサス システム 増大した半減期を有する免疫グロブリン様ドメイン
WO1998023289A1 (en) 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
ES2434961T5 (es) 1998-04-20 2018-01-18 Roche Glycart Ag Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo
HU230769B1 (hu) 1999-01-15 2018-03-28 Genentech Inc. Módosított effektor-funkciójú polipeptid-változatok
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
EP1176195B1 (en) 1999-04-09 2013-05-22 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
CA2388245C (en) 1999-10-19 2012-01-10 Kyowa Kirin Co., Ltd. The use of serum-free adapted rat cells for producing heterologous polypeptides
EP2322644A1 (en) 2000-06-28 2011-05-18 GlycoFi, Inc. Methods for producing modified glycoproteins
CA2424977C (en) 2000-10-06 2008-03-18 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
ES2639222T5 (es) 2000-10-06 2023-11-24 Kyowa Kirin Co Ltd Células que producen unas composiciones de anticuerpo
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
PT1355919E (pt) 2000-12-12 2011-03-02 Medimmune Llc Moléculas com semivida longa, composições que as contêm e suas utilizações
US7658921B2 (en) 2000-12-12 2010-02-09 Medimmune, Llc Molecules with extended half-lives, compositions and uses thereof
MXPA05000511A (es) 2001-07-12 2005-09-30 Jefferson Foote Anticuepros super humanizados.
EP2180044A1 (en) 2001-08-03 2010-04-28 GlycArt Biotechnology AG Antibody glycosylation variants having increased anti-body-dependent cellular cytotoxicity
CA2478297C (en) 2002-03-19 2013-05-14 Plant Research International B.V. Optimizing glycan processing in plants
CN103540600B (zh) 2003-01-22 2017-12-01 罗氏格黎卡特股份公司 融合构建体及其用来生产Fc受体结合亲和性和效应子功能提高的抗体的用途
JP2008539753A (ja) 2005-05-09 2008-11-20 グリクアート バイオテクノロジー アクチェンゲゼルシャフト 修飾fc領域およびfc受容体との結合変更を有する抗原結合分子
BRPI0707290A2 (pt) 2006-01-17 2011-08-16 Biolex Therapeutics Inc composições e métodos para humanização e otimização de n-glicanas em plantas
US7846724B2 (en) 2006-04-11 2010-12-07 Hoffmann-La Roche Inc. Method for selecting CHO cell for production of glycosylated antibodies
ES2776406T3 (es) 2007-07-12 2020-07-30 Gitr Inc Terapias de combinación que emplean moléculas de enlazamiento a GITR
CN104119438A (zh) 2009-01-29 2014-10-29 米迪缪尼有限公司 延长体内半衰期的人抗il-6抗体及其在治疗肿瘤、自身免疫性疾病和炎症性疾病中的应用
SG10201602394QA (en) 2011-03-29 2016-05-30 Roche Glycart Ag Antibody FC Variants
RU2017107847A (ru) * 2014-09-03 2018-10-03 Медиммун Лимитед Стабильный состав на основе антитела к il-4r-альфа
FI4045533T3 (fi) * 2020-03-26 2024-02-02 Univ Vanderbilt Ihmisen monoklonaalisia vasta-aineita vakavalle akuutille koronavirus 2 -hengityselinoireyhtymälle (sars-cov-2)
AU2021275361A1 (en) * 2020-05-17 2023-01-19 Astrazeneca Uk Limited SARS-CoV-2 antibodies and methods of selecting and using the same

Similar Documents

Publication Publication Date Title
JP2024150751A5 (https=)
KR102757960B1 (ko) 간세포암(hepatocellular carcinoma: HCC)에 대한 면역 치료
JP2022023051A (ja) 瘻孔を伴うクローン病の治療用ベドリズマブ
JP2017536354A5 (https=)
RU2012141556A (ru) Способы и композиции для лечения болезни дего
CN105452298A (zh) 改善药代动力学的具有跨pH范围差异结合的抗TFPI抗体变体
JP2018529635A5 (https=)
JP2021511387A5 (https=)
RU2021136970A (ru) Способ лечения или предупреждения болезней печени
JP2021525806A5 (https=)
BR112020017445A2 (pt) anticorpos anti cd6 para tratar asma severa
JP2020504135A5 (https=)
JP2022500382A5 (https=)
JPWO2022044573A5 (https=)
JPWO2021224499A5 (https=)
JP2021521201A5 (https=)
JPWO2022053655A5 (https=)
JPWO2022034044A5 (https=)
JP2020533022A5 (https=)
CN107249630A (zh) 通过il‑20r的拮抗作用治疗慢性阻塞性肺疾病的急性加重
JPWO2019228514A5 (https=)
JPWO2019147863A5 (https=)
JPWO2021092380A5 (https=)
JP2023522971A (ja) 呼吸器疾患の治療のための汎elr+cxcケモカイン抗体
TWI922217B (zh) 用於治療類風濕性關節炎的抗體及其用途